A detailed history of Achmea Investment Management B.V. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Achmea Investment Management B.V. holds 211,630 shares of BMY stock, worth $12.5 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
211,630
Previous 306,813 31.02%
Holding current value
$12.5 Million
Previous $12.7 Million 14.06%
% of portfolio
0.18%
Previous 0.23%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$39.66 - $51.75 $3.77 Million - $4.93 Million
-95,183 Reduced 31.02%
211,630 $11 Million
Q2 2024

Aug 08, 2024

BUY
$40.25 - $52.99 $1.17 Million - $1.54 Million
29,110 Added 10.48%
306,813 $12.7 Million
Q1 2024

May 08, 2024

BUY
$47.98 - $54.4 $354,236 - $401,635
7,383 Added 2.73%
277,703 $15.1 Million
Q4 2023

Feb 12, 2024

SELL
$48.48 - $57.85 $6.34 Million - $7.56 Million
-130,743 Reduced 32.6%
270,320 $13.9 Million
Q3 2023

Nov 06, 2023

SELL
$57.89 - $64.73 $2.55 Million - $2.86 Million
-44,120 Reduced 9.91%
401,063 $23.3 Million
Q2 2023

Jul 24, 2023

BUY
$63.71 - $70.74 $2.47 Million - $2.74 Million
38,793 Added 9.55%
445,183 $28.5 Million
Q1 2023

May 04, 2023

BUY
$65.71 - $74.53 $4.02 Million - $4.56 Million
61,211 Added 17.73%
406,390 $28.2 Million
Q4 2022

Feb 09, 2023

BUY
$68.48 - $81.09 $965,431 - $1.14 Million
14,098 Added 4.26%
345,179 $23.3 Million
Q3 2022

Oct 27, 2022

SELL
$0.13 - $76.84 $1,304 - $771,166
-10,036 Reduced 2.94%
331,081 $23.5 Million
Q2 2022

Aug 10, 2022

BUY
$72.62 - $79.98 $10.7 Million - $11.8 Million
147,744 Added 76.4%
341,117 $26.3 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $6.43 Million - $7.71 Million
104,575 Added 117.77%
193,373 $14.1 Million
Q4 2021

Feb 10, 2022

SELL
$53.63 - $62.52 $1.57 Million - $1.83 Million
-29,328 Reduced 24.83%
88,798 $5.54 Million
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $219,106 - $256,654
3,703 Added 3.24%
118,126 $6.99 Million
Q2 2021

Aug 06, 2021

SELL
$61.91 - $67.42 $2.89 Million - $3.15 Million
-46,695 Reduced 28.98%
114,423 $7.65 Million
Q1 2021

May 11, 2021

SELL
$59.34 - $66.74 $6.01 Million - $6.76 Million
-101,242 Reduced 38.59%
161,118 $10.2 Million
Q4 2020

Feb 22, 2021

SELL
$57.74 - $65.43 $1.9 Million - $2.15 Million
-32,913 Reduced 11.15%
262,360 $16.3 Million
Q3 2020

Nov 02, 2020

BUY
$57.43 - $63.64 $17 Million - $18.8 Million
295,273 New
295,273 $17.8 Million
Q1 2020

May 13, 2020

SELL
$46.4 - $67.43 $11 Million - $15.9 Million
-236,459 Closed
0 $0
Q4 2019

Feb 10, 2020

BUY
$49.21 - $64.19 $5.6 Million - $7.31 Million
113,897 Added 92.93%
236,459 $15.2 Million
Q3 2019

Nov 14, 2019

SELL
$42.77 - $50.71 $575,855 - $682,759
-13,464 Reduced 9.9%
122,562 $6.22 Million
Q2 2019

Aug 06, 2019

BUY
$44.62 - $49.34 $708,565 - $783,519
15,880 Added 13.22%
136,026 $6.17 Million
Q1 2019

May 15, 2019

SELL
$45.12 - $53.8 $1.88 Million - $2.24 Million
-41,662 Reduced 25.75%
120,146 $5.73 Million
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $959,791 - $1.24 Million
19,684 Added 13.85%
161,808 $8.41 Million
Q3 2018

Nov 06, 2018

SELL
$55.19 - $62.25 $1.68 Million - $1.89 Million
-30,386 Reduced 17.61%
142,124 $8.82 Million
Q2 2018

Jul 27, 2018

BUY
$50.53 - $62.98 $475,537 - $592,704
9,411 Added 5.77%
172,510 $9.54 Million
Q1 2018

May 15, 2018

BUY
$59.92 - $68.98 $4.73 Million - $5.45 Million
78,957 Added 93.84%
163,099 $10.3 Million
Q4 2017

Feb 12, 2018

BUY
$59.94 - $65.35 $1.78 Million - $1.94 Million
29,732 Added 54.64%
84,142 $5.16 Million
Q3 2017

Nov 09, 2017

BUY
$55.23 - $63.74 $1.12 Million - $1.29 Million
20,229 Added 59.18%
54,410 $3.47 Million
Q2 2017

Aug 29, 2017

BUY
N/A
34,181
34,181 $1.9 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Achmea Investment Management B.V. Portfolio

Follow Achmea Investment Management B.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Achmea Investment Management B.V., based on Form 13F filings with the SEC.

News

Stay updated on Achmea Investment Management B.V. with notifications on news.